![](/img/cover-not-exists.png)
Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (Sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy
Allan J. Pantuck, Nazy Zomorodian, Arie S. BelldegrunVolume:
8
Language:
english
Pages:
2
DOI:
10.1007/s11934-007-0014-8
Date:
January, 2007
File:
PDF, 66 KB
english, 2007